At BRL Medicine Inc., we aim to become the world's leading Cellular & Gene pharmaceutical company in the era of new commercial civilization, with the mission of "Through innovation led by gene editing, develop breakthrough human therapeutics and benefit the whole world". With its independent R&D center and the "Shanghai Research Center for Gene Editing and Cell Therapy", jointly established by BRL Medicine and university, BRL Medicine has obtained more than 100 patent achievements, and initiated 19 Investigator-Initiated clinical Trials (IIT) in 20 leading hospitals in China, with many pipeline projects have entered into IND application stage. Among them, gene editing projects for β-thalassemia, PD1 knockout non-viral targeted integration CAR-T and UCART have achieved excellent clinical results and have published several academic papers in famous academic journals such as Nature 、Cell、Nature Medicine、Nature biotechnology. BRL Medicine has built five technology platforms with independent intellectual property rights, including The Gene Editing Technology Innovation Platform, Hematopoietic Stem Cell Platform, The Quikin CAR-T Platform, Universal Cell Platform and Enhanced T Cell Platforms, and has a 7000 square meter GMP pilot plant and an operating team of nearly 100 people, which strongly guarantees the rapid transformation and application of innovative research. BRL Medicine continuously promotes rapid update and iteration of R&D products through patient needs and clinical feedback. Driven by the era of new commercial civilization, BRL Medicine holds an open, shared, and win-win attitude, and works with global innovative biomedical ecological chain companies to accelerate the transformation and implementation of innovative drugs, so as to benefit global patients with genetic diseases and malignant tumors!
Dedicated to the development and translation of gene editing and cell therapy and gene therapy for genetic diseases caused by gene mutations
Nearly 100 people
Contains 10% PhD and 23.5% Master
125+
Has applied for 125 invention patents at home and abroad
Has five core technology platforms with independent intellectual property rights
Relying on its strong technical strength and scientific research team in the field of gene editing and immunology, BRL Medicine is dedicated to the development and translation of gene editing and cell therapy, as well as gene therapy for genetic diseases caused by gene mutations.
Awarded the "2024 Shanghai Science and Technology Progress First Prize"
World's first β0/β0 severe thalassemia patient cured for 5 years by BRL-101.
Awarded "BioCon Awards 2025-Annual Investable Innovation Enterprise".
Published 2 papers in Nat Biotechnol: Achieved first global "precise repair" of in vivo mitochondrial DNA.
Won CGCS Awards "CGT R&D Excellence Rising Star Award".
Listed on "2025 BEYOND Awards MedTech List".
Published in Cell Res: Confirmed success of world's first allogeneic UCAR-T (BRL-301) treating r/r SLE.
Ranked Top 100 on VB100 "China Innovative Pharma & Biologics List".
BRL-101 & BRL-303 progress selected for ASGCT & EHA 2025.
Published major review in Cancer Cell guiding solid tumor immunotherapy.
IND approval for BRL-301 UCAR-T in new indication (r/r B-cell NHL).
Won APAC CGT Star "Annual Most Influential Innovative Therapy Company".
Published in Nat Biotechnol: Developed novel RNA editor "PA-rABE" for genetic disease therapy.
BRL-303 research named among "2024 China Top 10 Scientific Advances".
BRL-303 research named among "2024 China Top 10 Biotech Advances".
Published in Mol Ther: Developed innovative CAR-T enhancing solid tumor efficacy.
BRL-303 research named "Cell Line: 2014-2024" by Cell.
BRL-303 research named among "2024 China Top 10 Life Sciences Advances".
BRL-303 research named among "2024 China Top 10 S&T Advances" (CAS/CAE selected).
Recognized as Shanghai Excellent Patent Model Unit.
BRL-303 research named "Best of Cell 2024".
BRL-303 research named among "2024 Top 10 Clinical Breakthroughs".
BRL-303 research named among "2024 Top 10 Int'l & Domestic S&T News" (Science and Technology Daily) .
Won "Annual Investment Value Award" (5th China Biopharma Innovation List).
Announced success of BRL-102 gene therapy for China's first foreign SCD patient.
Completed ~200M RMB B+ financing.
Won "Outstanding Award" at 4th Biotech Rising Star Competition.
World's first IND approval in China for "BRL-203" (non-viral PD1-targeted CAR-T for lupus).
Awarded "top 100 pharmaceutical innovative seed enterprises in China in 2024".
Ranked Top 20 "2024 BioManufacturing Rising Star".
BRL-303 research featured in Nature headline.
First BRL-201 (PD1-CAR-T) patient cancer-free >4 years.
BRL-303 research highly praised by Prof. Carl June in Cell.
Ranked Top 10 Most Influential CGT Company (Huayi Chart).
Won "Outstanding Project" at Precision Medicine Innovation Competition.
Won "Rare Disease Industry Promotion Award" (4th Golden Snail Award).
BRL-303 UCAR-T lupus research highlighted in Nat Rev Rheumatol.
Published in Mol Cell: Developed novel compact, hyperactive IscB-based gene editor.
World's first β0/β0 severe thalassemia patient cured for 4 years by BRL-101.
Published in Cell: World's first success with allogeneic UCAR-T (BRL-303) treating autoimmune disease.
Ranked Top 30 Innovative Novel Therapeutics Biopharma (China Biopharma Innovation List).
Awarded "2024 CGT Rising Star Enterprise of the Year".
BRL-201 progress presented at ASCO.
BRL-101 & BRL-201 progress presented at EHA.
BRL-101 progress presented at ASGCT (2nd consecutive year), and the latest clinical progress was orally reported.
Awarded "2024 top 100 list of innovative pharmaceutical and biological products in China" by VB100, and "2024 VBEF list of innovative products in the medical and health industry".
Reported promising efficacy of UCAR-T (with Zhejiang FAH) in refractory lupus, enabling patient cessation of traditional drugs.
Won "CGT Star: Outstanding Innovative Pipeline Award".
Published in Nat Chem Biol: Developed haA3A-CBE high-precision editor.
Won Future Industry Rising Star Award (Project Group).
Won "Zhuoyao Rising Star Enterprise".
BRL-101 research featured on CCTV Dialogue.
Won "2023 Most Investable Rising Star" (China Biopharma Innovation List).
Ranked Top 10 Most Promising Novel Cell Therapy Company (Huayi Chart).
BRL-101 & BRL-201 progress presented at ASH.
Orally Presented BRL-201 (next-gen non-viral PD1-CAR-T) data at SITC.
Ranked Top 10 on "2023 Dalinghao Bay Innovation & Entrepreneurship Influence List".
Awarded "top 100 pharmaceutical innovative seed enterprises in China in 2023".
World's first BRL-201 (non-viral PD1-CAR-T) patient cancer-free >3 years.
Strategic partnership with Porton Biologics to accelerate CGT industrialization.
Advanced to China Innovation & Entrepreneurship National Finals.
World's first β0/β0 severe thalassemia patient cured >3 years by BRL-101.
BRL-201 progress presented at ASGCT & SITC, and the latest clinical progress was orally reported.
IND approval for next-gen UCAR-T "BRL-301" in China.
Published in Mol Ther: Developed innovative CAR-T enhancing solid tumor efficacy.
Awarded "2023 China Biopharma Value: Top 10 Most Influential Innovative Therapy Companies".
Awarded "Top 30 Innovative Novel Therapeutics Biopharma".
Awarded "BioCon Awards 2023-Most Investable Rising Biotech Star".
Published in Nat Biotechnol: Developed ACBEs transversion editor.
Awarded "2023 Top 10 Most Influential CGT Companies".
BRL-201 published in Lancet sub-journal.
Awarded "Thalassemia Caring Tech Enterprise".
First public presentation of BRL-101 data at ASGCT.
IND applications for CD19 UCAR-T products BRL-301 & BRL-301A accepted in China.
BRL-101 cured 2 adult severe thalassemia patients in Phase 1 trial.
BRL-201 named among "2022 China Important Medical Advances".
Awarded "CGT Star 2023: Best Technology Breakthrough Award".
Awarded "2022 Top 100 Breakthrough Innovation Companies".
BRL-201 entered registrational clinical study.
Recognized as Shanghai "Specialized, Sophisticated, Distinctive, Innovative" SME.
First thalassemia patient cured in BRL-101 Phase 1 trial.
BRL-201 (non-viral CAR-T) named among "2022 Top 10 Hematology Research Advances in China".
Awarded "2022 Most Promising Newcomer", "2022 Most Applicable Key Tech Platform" (hematopoietic stem cell platform, non viral fixed-point integration car-t platform).
IND approval for "Targeting CD19 Non viral PD1 Targeted Integration CAR-T Cell Injection" (pipeline code: BRL-201) in China.
First patient dosed in BRL-101 Phase 1 trial.
Non-viral CAR-T tech won "2022 S&T Achievement Transformation Award" (Southern Weekly).
Recognized as Shanghai Patent Model Unit.
Founder Prof. Mingyao Liu named "Annual Influential Leader in China CGT".
Ranked Top 10 Most Promising Innovative Therapy Company.
Completed >200M RMB Series B financing.
Published in Nat Biotechnol: Developed high-precision Td-CGBE/Td-CBEs editors.
Thalassemia research were selected into the report of "The Payment for Rare Disease Drugs to Promote Common Prosperity in China (2022) ".
Published in Nat Chem Biol: Developed precise ABE9 base editor.
Recognized as National IP Advantageous Enterprise.
For two consecutive years: "Top 30 Most Innovative New Technology Pharmaceutical Enterprises in China" and "Top 100 Innovative Seed Pharmaceutical Enterprises in China."
Published in Nature: BRL-201 (non-viral PD1-targeted CAR-T) achieved >2-year cancer-free survival in NHL patient.
IND approval for "BRL-101 autologous hematopoietic stem and progenitor cells injection" (Pipeline code: BRL-101) in China.
Awarded "2022 China biomedical industry value list - top20 most influential innovative therapy enterprises".
Published in Nat Med: BRL-101 gene therapy enabled thalassemia child transfusion independence >2 years.
Awarded "2022 top 100 future medical treatment - China's top 100 innovative medicine list" and "2022 top ten value fields list - TOP10 in gene therapy".
Awarded "top 100 pharmaceutical innovative seed enterprises in China in 2021".
Gene therapy achieved transfusion independence for 6 thalassemia children nationwide.
Recognized as Shanghai Excellent Patent Pilot Unit.
Awarded "2021 biological innovative drug most growth annual award".
Appointed research partner by Hunan Genetics Society Rare Disease Committee.
Awarded "2021 top 100 future medical treatment - China's top 100 innovative medicine list" and "2021 biomedical value field list - TOP10 in the field of cell and gene therapy".
Ranked Top 30 Innovative Novel Therapeutics Biopharma Company (China).
Established internship base with ECNU.
Cured 3 thalassemia children in Guangxi (with 923 Hospital).
First ALL patient cured with next-gen UCAR-T therapy (with Zhejiang University FAH).
Thalassemia breakthrough featured in ZHONGGUO DIZHONGHAI PINXUE LANPISHU (2020).
Awarded "2020 China Health New Force Enterprise".
Launched Global Partner Recruitment Program.
6000 sqm GMP pilot base operational.
First successful treatment of ALL patient with CD19-UCART (with Zhengzhou University FAH).
Obtained IP Management System Certification.
Released world's first clinical data: CD19-PD1-Quikin-CART successfully treated lymphoma (with Zhejiang University FAH).
Released world's first clinical data: CRISPR cured β0/β0 severe thalassemia (with Xiangya Hospital).
Published in Nat Biotechnol: Developed novel dual base editing system.
Published in Nat Cell Biol: Developed ultra-active HyCBE base editor.
Published in Nat Med: Demonstrated next-gen base editing potential for hereditary blood diseases.
Ranked Top 5 in Universal CAR-T (Future Healthcare 100 China).
Awarded multi-million RMB funding from Shanghai Zhangjiang National Key Project (H25).
Ranked among China's Top 50 Most Innovative Biopharma Companies.
Recognized as Shanghai Patent Pilot Enterprise.
Published in Nat Med: Gene therapy potential for curing hereditary blood diseases.
Initiated IIT for CD19-UCART.
1000 sqm GMP-like pilot base operational.
Awarded National High-Tech Enterprise status.
Recombination of BRL Medicine and establishment of "Shanghai Research Center for Gene Editing and Cell Therapy".
BRL Medicine Inc. was incorporated in Shanghai.
Published in Nat Biotechnol: First global application of CRISPR/Cas9 in mammalian gene editing.
